Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
-$0.03 today
- Market cap
- $109.26M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
Volume 2.90M
Average 7.64M
CMPX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Compass Therapeutics, Inc.NASDAQ: CMPX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $5.07M rose 101.8% year over year, ahead of the +20.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 178.0% from the prior quarter. Over 3 fiscal years it compounded at +16.2% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +101.8% holds above the trailing-twelve-month pace of +20.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 8.37M USD
- Year-over-year change
- -2.2%
- 4-year CAGR
- +20.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.37M | -2.2% |
| FY2024 | 2024-12-31 | 8.56M | +39.9% |
| FY2023 | 2023-12-31 | 6.12M | +14.8% |
| FY2022 | 2022-12-31 | 5.33M | +32.3% |
| FY2021 | 2021-12-31 | 4.03M | — |
Stock-Based Compensation vs competitors
How CMPX compares with its peers on the latest reported figures
- CMPX's LTM Mar 2026 stock-based compensation of $10.93M is the 5th largest of the 11 companies compared; the peer median is $7.97M.
- Its year-over-year change of +20.5% is the 4th highest of 10, against a peer median of +2.5%.
- Over three fiscal years its annual growth of +16.2% compares with a peer median of +5.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.48M | -28.2% | +8.7% | 22.1% | |
| LTM Mar 2026 | $14.45M | -16.0% | -37.2% | 26.0% | |
| LTM Mar 2026 | $13.16M | -4.7% | -2.3% | — | |
| LTM Mar 2026 | $12.55M | +2.5% | +2.8% | 18.0% | |
| LTM Mar 2026 | $10.93M | +20.5% | +16.2% | — | |
| LTM Mar 2026 | $9.22M | +22.1% | -9.9% | 206.5% | |
| LTM Mar 2026 | $6.73M | +88.8% | +25.6% | — | |
| LTM Mar 2026 | $5.74M | +13.3% | — | 58.0% | |
| LTM Dec 2025 | $5.38M | — | — | 4.6% | |
| LTM Mar 2026 | $4.07M | +87.9% | +43.4% | — | |
| LTM Mar 2026 | $2.68M | -107.0% | +13.8% | 4.2% | |
| Peer median (excluding CMPX) | $7.97M | +2.5% | +5.8% | 22.1% | |
Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (82.18M) | (39.23M) | (42.49M) | (49.38M) | (66.49M) |
| Depreciation & Amortization | 1.62M | 1.9M | 1.89M | 1.75M | (1.4M) |
| Deferred Income Tax | 50.58M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.03M | 5.33M | 6.12M | 8.56M | 8.37M |
| Change in Working Capital | 6.25M | (1.26M) | (2.91M) | (4.14M) | 9.18M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (194K) | 2.52M | 708K | (1.84M) | (664K) |
| Other Working Capital | 6.44M | (3.78M) | (3.62M) | (2.3M) | 9.84M |
| Other Non-Cash Items | 41K | (871K) | 5.97M | (1.65M) | 1.2M |
| Operating Cash Flow | (19.67M) | (34.13M) | (40.62M) | (44.86M) | (49.14M) |
| Capital Expenditures | (1.57M) | (212K) | (30K) | (44K) | (25K) |
| Acquisitions (Net) | 116K | 176K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (200.12M) | (155.42M) | (88.16M) | (194.56M) |
| Sales of Investments | 0 | 48.96M | 182.41M | 134.97M | 101.28M |
| Other Investing Activities | (318K) | (150.99K) | 27K | 0 | 0 |
| Investing Cash Flow | (1.77M) | (151.2M) | 26.97M | 46.77M | (93.31M) |
| Debt Repayment | — | — | — | 0 | 0 |
| Common Stock Issued | 128.27M | 76.24M | 3.09M | 18.11M | 130.64M |
| Common Stock Repurchased | 0 | 0 | (159) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (281K) | (480K) | (159K) | (775K) | (1.03M) |
| Financing Cash Flow | 118.61M | 75.76M | 2.94M | 17.34M | 129.61M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 97.18M | (109.57M) | (10.72M) | 19.26M | (12.84M) |
| Free Cash Flow | (21.23M) | (34.34M) | (40.65M) | (44.9M) | (49.17M) |
Compass Therapeutics, Inc.
NASDAQ:CMPX
Intrinsic Alpha fair value
Locked
Current Price
$0.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.